Introduction
The development of an effective vaccine against HIV-1 remains elusive and is an obstacle in combating HIV-1 infection. Approaches preventing HIV-1 transmission, in particular those that target the dendritic cell (DC)-mediated transmission of HIV-1 are very attractive, since it precedes HIV-1 replication and thereby mutagenesis in the host. Moreover, our current knowledge about the underlying process of HIV-1 transmission allows us to develop specific preventive strategies.
The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 is extensively glycosylated and contains approximately 24 potential N-linked glycosylation sites. These glycosylation sites are occupied with glycans that form almost 50k of the gp120 molecular weight. The gp120 glycans represent high-mannose, hybrid and complex classes and serve as ligands for different lectins (Geyer et al., 1988) . HIV-1 binding mediated by the DC-specific C-type lectin DC-SIGN (dendritic cell-specific ICAM-3 grabbing non-integrin; CD209) facilitates HIV-1 transmission by DCs to T cells (Geijtenbeek et al., 2000a,b) . Moreover, internalized virus is stored in multivesicular bodies and specifically transmitted to CD4+ T cells through infectious synapses formed between DCs and T cells (McDonald et al., 2003) . These processes are very specific and substantially increase T cell infection. The membrane-associated C-type lectin DC-SIGN is one of the main players in the described establishment and dissemination of HIV-1 and other infections (Curtis et al., 1992; Geijtenbeek et al., 2000a,b; Arrighi et al., 2004; Lekkerkerker et al., 2004; Nabatov et al., 2006; Zhang et al., 2006; Zhang et al., 2008) . Therefore, preventing HIV-1 interaction with DCs, and in particular DC-SIGN, might represent a powerful method to prevent HIV-1 transmission and infection of the host. Several strategies have been aimed at inhibiting DC-SIGN function using soluble carbohydrates or antibodies against DC-SIGN. However, a more efficient method might be to target gp120 with specific inhibitors in order to prevent DC-SIGN binding.
The importance of gp120 glycans for the many aspects of HIV-1 infection makes them suitable targets for anti-HIV-1 treatment or prophylaxis (Balzarini, 2007; Witvrouw et al., 2005) . The ability of different sugar-binding proteins to neutralize HIV-1 in vitro has been shown for a number of lectins (reviewed in (Balzarini, 2006) ). Of special interest are the lectins that resemble the structure and specificities of the natural HIV-1-binding lectins such as DC-SIGN.
Mermaid is a novel Ca 2+ -dependent mannose-specific C-type lectin that is exclusively secreted onto the posterior, bacteriumassociated region of Laxus oneistus cuticle. This C-type lectin mediates bacterial symbiont aggregation on the worm cuticle. The carbohydrate recognition domain of this mannose-binding protein is structurally and functionally similar to the one of human DC-SIGN Zhang et al., 2006) . In the current study we have demonstrated that Mermaid in the form of a biological chimera (Zhang et al., 2008 ) is able to block DCmediated HIV-1 transmission by preventing DC-SIGN binding to HIVVirology 378 (2008) 323-328 1. The obtained results are important for the development of microbicides, which act by blocking DC-SIGN-mediated HIV-1 transmission.
Results

Mermaid blocks binding of DC-SIGN to gp120 and ManLAM
Mermaid is a C-type lectin and its structure has high similarity with human DC-SIGN, suggesting that it might interact with similar oligosaccharide structures as DC-SIGN . Since HIV-1 targets DC-SIGN on DCs for viral transmission to T cells (Geijtenbeek et al., 2000a) , we investigated whether Mermaid inhibits the interaction between DC-SIGN and HIV-1 gp120. Soluble DC-SIGN interacted with both HIV-1 gp120 and its mycobacterial ligand ManLAM (Fig. 1A) . Preincubation of HIV-1 gp120 and ManLAM with Mermaid significantly inhibits the interaction of the structures with DC-SIGN (Fig. 1A) . The inhibition by Mermaid was dose-dependent (IC 50~8 .8 and 10.7μg/ml for gp120 and ManLAM, respectively) and to background levels at the highest Mermaid concentration. The inhibition was similar to that of the known DC-SIGN inhibitor mannan (IC 50~5 .3 and 4.8μg/ml for gp120 and ManLAM, respectively) (Figs. 1B and C). These data strongly suggest that Mermaid competes with DC-SIGN for binding to the carbohydrate structures on gp120 and ManLAM.
Mermaid and DC-SIGN share glycan specificity
To clarify how Mermaid inhibits of DC-SIGN interactions with mannose-containing pathogenic ligands, we compared the specificity of the two C-type lectins using synthetic glycoconjugates linked to a biotinylated polyacrylamide: galactose (Gal), trimannose (Man3) and glucitol (Gluc) as a negative control. DC-SIGN interacted with Man3, but not with Galactose (Fig. 2) . Mermaid also bound to Man3 and the interaction was blocked with the calcium chelator EGTA. In contrast to DC-SIGN, Mermaid also exhibited specific binding to galactose that was blocked by EGTA (Fig. 2) . Both Mermaid and soluble DC-SIGN did not bind to the control glucitol. Thus, Mermaid interacts with similar mannose-binding carbohydrates as DC-SIGN.
Mermaid blocks binding of gp120 to DCs
Cellular DC-SIGN has a higher avidity for HIV-1 gp120 than soluble DC-SIGN due to cluster formation (Cambi et al., 2005) . Therefore, we investigated whether Mermaid binding to gp120 inhibits the gp120 interaction with cellular DC-SIGN expressed by Raji transfectants. Cellular DC-SIGN interacted with HIV-1 gp120 (Fig. 3) . Preincubation of HIV-1 gp120-coated beads with Mermaid strongly decreased binding to cellular DC-SIGN expressed by Raji transfectants (Fig. 3) . HIV-1 gp120 binding to immature DCs is mediated by DC-SIGN (Geijtenbeek et al., 2000a) . Mermaid inhibited HIV-1 gp120 binding to DCs to the level of soluble DC-SIGN (Fig. 3) , whereas EGTA inhibited the interaction more strongly. This binding assay is based on the high avidity interaction between DCs and gp120-coated beads and our data suggest that inhibition by targeting gp120 is less efficient than by the direct inhibition of DC-SIGN using EGTA. Moreover, it is possible that other receptors are also involved in the gp120 binding. These data demonstrate that Mermaid inhibits HIV-1 gp120 binding to DC-SIGN expressed by both transfectants and immature DCs.
Mermaid specifically blocks DC-SIGN mediated transmission
DC-SIGN binding to HIV-1 leads to viral transmission to T cells (Geijtenbeek et al., 2000a) . Therefore, we investigated whether Mermaid prevents HIV-1 transmission by Raji-DC-SIGN cells. HIV-1 was efficiently transmitted to T cells by DC-SIGN (Fig. 4A) . Strikingly, HIV-1 preincubation with Mermaid abrogated HIV-1 transmission mediated by DC-SIGN in a concentration dependent manner (IC 50~3 .1μg/ml). Notably, soluble DC-SIGN did not prevent HIV-1 transmission by Raji-DC-SIGN, whereas direct block of DC-SIGN by mannan inhibited the transmission efficiently (Fig. 4A) . These data strongly suggest that Mermaid is an inhibitor of DC-SIGN-mediated transmission of HIV-1.
Next, we assessed the ability of Mermaid to block transmission of HIV from DCs to CD4+ T cells. DCs were incubated with HIV-1 and T cells were added after 2hours without washing. As demonstrated, DCs enhanced infection of T cells (Fig. 4B) . Strikingly, preincubation of HIV-1 with Mermaid inhibited HIV-1 transmission to a similar level as T cell infection alone, demonstrating that Mermaid binding to HIV-1 prevents DC-SIGN-mediated transmission (Fig. 4B) . Mermaid itself did not prevent T cell infection, strongly suggesting that it prevents HIV-1 infection of T cells by inhibiting DC-SIGN-mediated transmission. Moreover, we did not observe any apoptosis of T cells and DCs in presence of Mermaid (Fig. 5) . Thus, Mermaid competes with DC-SIGN for HIV-1 gp120 binding and prevents HIV-1 transmission by DC-SIGN on DCs. In addition, Mermaid can be used safely in vitro and its activity is not a result of cytotoxicity.
Discussion
Anti-retroviral treatment is the best option for long-lasting HIV-1 suppression and, subsequently, for reduction of morbidity and mortality. However, current drugs do not eradicate HIV-1 infection and lifelong treatment might be needed (Simon et al., 2006) . On the other hand, classical approaches to vaccine development have not yielded a HIV/AIDS vaccine yet (Robinson, 2007) . Thus, new strategies need to be developed to reach significant progress in anti-HIV therapy or prevention. Development of topical agents (microbicides) in the form of gels and creams preventing sexually transmitted infections is one of the most growing new anti-HIV-1 approaches (van de Wijgert and Shattock, 2007) .
The importance of gp120 glycosylation in viral physiology suggests the possibility of targeting the glycosylation of HIV-1 (Balzarini, 2007; Witvrouw et al., 2005) . The gp120 glycosylation-specific neutralizing monoclonal antibody 2G12 is one of the few known antibodies that are able to neutralize broad spectrum of HIV-1 strains, strongly supporting the idea of the anti-glycosylation approach in anti-HIV therapy (Trkola et al., 1996; Sanders et al., 2002) . Thus identification of new compounds that prevent infection remains an current challenge in HIV-1 therapy.
The current study focuses on the anti-HIV effect of the recently identified lectin Mermaid, which has been shown to share structural features with DC-SIGN . In particular we were interested in the ability of Mermaid to inhibit DC-SIGN-mediated HIV-1 transmission of DCs to T cells, one of the first events in HIV transmission from person-to-person in sexual intercourse (van Kooyk and Geijtenbeek, 2003) . Our data strongly suggest that Mermaid has a similar binding specificity for mannose-containing carbohydrates as DC-SIGN, since both interact with similar ligands and Mermaid prevented DC-SIGN binding to ManLAM and gp120. DC-SIGN expressed by DCs or transfectants captures HIV-1 and increases transmission to T cells (Geijtenbeek et al., 2000a ). Here we show that Mermaid is able to block this transmission without affecting the viability of the T cells. Therefore, Mermaid prevents HIV binding by DC-SIGN and subsequent transmission to T cells in vitro.
The ability of Mermaid to block DC-SIGN recognition and binding of gp120 suggests that these two lectins may compete for common binding sites. We compared the sugar-specificity of DC-SIGN and Mermaid and found that, indeed, their structural similarity is reflected in their common ability to bind mannose rich oligosaccharide sugars. The significant decrease of the binding to glycans in the presence of EGTA suggests that the binding to these sugars is Ca 2+ dependent, which is typical of C-type lectin. In contrast to DC-SIGN, Mermaid has also specificity for galactose residues. These data suggest that although similar, the C-type lectins do not have identical carbohydrate recognition profiles. DCs capture HIV-1 particles at the periphery and transport them to T cell areas, where HIV-1 efficiently infects T cells. Therefore, we investigated the ability of Mermaid to prevent DCmediated transmission. Mermaid inhibited gp120 binding to DCs. Notably, the inhibition was similar to that observed with soluble DC-SIGN, but less than observed with EGTA, suggesting that Mermaid specifically blocks DC-SIGN binding but not the interaction of HIV-1 with other HIV-1 attachment receptors such as syndecan-3 (de Witte et al., 2007) . In agreement with the inhibition of HIV-1 binding, Mermaid also inhibited DC-mediated HIV transmission. In contrast, we did not observe inhibition of HIV-1 transmission using soluble DC-SIGN, which might be due to a lower affinity than Mermaid for gp120. Mermaid did not significantly inhibit direct T cell infection, further supporting our data that Mermaid inhibits DC-SIGN-mediated transmission but not HIV-1-CD4 interactions.
Thus, we have identified Mermaid as a non-cytotoxic agent that shares the glycan specificity with DC-SIGN, inhibits DC-SIGNgp120 interaction, as well as DC-mediated HIV-1 transmission to CD4+ T cells in vitro. As a potential microbicide, Mermaid will attach to the virus upon entry and thereby prevent capture by DCs and subsequent transmission. Further experiments should also focus on the immunogenicity of Mermaid, as its limited identity with DC-SIGN, which might induce inflammatory responses. In conclusion, our data strongly suggest that a soluble C-type lectin such as Mermaid might be an attractive anti-HIV-1 microbicide.
Materials and methods
Abs, natural and synthetic glycoconjugates
The mAb anti-DC-SIGN antibody blocking lectin specific binding (mAbs AZN-D1) was used as described earlier (Geijtenbeek et al., 2002) . Mannan purified from Saccharomyces cerevisiae and recombinant HIV-1 SF2 gp120 expressed in CHO cells were obtained from Sigma-Aldrich (St. Louis, MO, USA) and the AIDS Resource Foundation (Rockville, MD, USA), respectively. Synthetic glycoconjugates were obtained from Syntesome (Munich, Germany) and comprised galactose (Gal); mannotriose (Manα 1-3(Manα1-6)Man; Man3) or Glucitol multivalently linked to a biotinylated polyacrylamide carrier. The biologically modified chimera of Mermaid with His-tag tail was obtained and purified as described previously .
Soluble DC-SIGN-Fc binding ELISA
DC-SIGN-Fc consists of the extracellular portion of DC-SIGN (aa residues 64-404) fused at the C-terminus to a human IgG1-Fc fragment as previously described (Geijtenbeek et al., 2002) . The DC-SIGN-Fc binding assay was performed as follows. Glycoconjugates (gp120 or ManLAM) were coated onto ELISA plates at 2 (for serial dilution experiment) or 5 μg/well; and coating took place for 18h at room temperature, followed by blocking with 2k BSA for 30 min at 37°C in TSM (20mM Tris-HCl (pH 7.4) containing 150 mM NaCl, 1 mM CaCl 2 , and 2mM MgCl 2 ). Soluble DC-SIGN-Fc (2 μg/ml in TSM buffer) was added and the adhesion was performed for 120min at room temperature. Unbound DC-SIGNFc was washed away and binding was determined by an antiIgG1-Fc ELISA using a peroxidase conjugate of goat anti-human-Fc. Specificity was determined in the presence of serial dilutions of Mermaid or mannan.
Glycan specificity assay
The DC-SIGN-Fc chimera and Mermaid (5μg/ml) were coated in 0.2M NaHCO3 on ELISA plates (Maxisorp plate; Nunc), and incubated overnight at 4°C. This was followed by blocking with TSM containing 1k BSA for 30 minutes at 37°C before addition of the biotinylated glycoconjugates (5 μg/ml in TSM) for 2hours at room temperature; the binding was determined by incubation of a peroxidase-labeled streptavidin for 30 minutes at room temperature. The specificity was determined by preincubation of the sorbed DC-SIGN-Fc and Mermaid with 10mM EGTA.
HIV-1 gp120 binding assay
Beads were prepared as previously described (Geijtenbeek et al., 2000b) . In short, streptavidin was covalently coupled to carboxylatemodified TransFluoSpheres (488/645 nm excitation/emission, 1.0μm; Invitrogen Corp.). The streptavidin beads were incubated with biotinylated F(ab')2 fragment goat-anti-human IgG (6 μg/ml; Jackson ImmunoResearch Laboratories Inc.) and subsequently incubated overnight with gp120-Fc chimera.
The beads preincubated with Mermaid (300μg/ml) for 30min at 37°C in medium were added to fifty thousand DC and incubated additional 40 min, after which the cells were washed with TSM containing 0.5k BSA. After washing, the cells were resuspended in 
Cells
Immature DCs were cultured from monocytes in the presence of IL-4 and GM-CSF (500 and 800U/ml, respectively; Schering-Plough, Brussels, Belgium). At day 7, the phenotype of the cultured DC was confirmed by flow cytometric analysis.
The PHA-activated enriched CD4 + T lymphocytes (CCR5 +/+ ) were obtained and cultured as described earlier (Nabatov et al., 2006) . The Raji cell line from the American Type Culture Collection (ATCC; Rockville, MD, USA), and the Raji cell line expressing DC-SIGN (Raji-DC-SIGN), were utilized in this study in transmission assay. Raji transfectants expressing DC-SIGN were utilized in DC-SIGN mediated binding experiments. Jurkat cells expressing CCR5 were generated by retroviral transduction with lentiviral vectors.
Viruses
Replication-competent HIV-1 stocks were generated by the passage of viruses through CD4 + lymphocytes, with tissue culture infectious dose (TCID 50 /ml) determined by limiting dilution on CD4 + -enriched lymphocytes. Subtype B molecular cloned viruses JR-CSF (R5) was used in the experiments.
Other replication-competent R5 HIV-1 viruses (gp120 from Bal strain) expressing GFP in the infected cells were generated by transfecting 293T cells with NL4.3eGFP-BaL proviral DNA plasmids (9μg) together with VSV-G envelope plasmid (1μg). The plasmids were generously provided by C. Aiken: pNL4.3eGFP-BaL, in which wild-type NL4.3 envelope was switched for the R5 BaL envelope and which encodes the GFP gene instead of the Nef gene. At day 2, VSV-G pseudotyped viruses were harvested and used to acutely infect Jurkat T cells. Two days post-infection, de novo viruses produced from Jurkat T cells were harvested, run over a 0.22μm filter and frozen for future use. Amounts of viruses produced were quantified by measuring amounts of viral capsid in the supernatant of transfected Jurkat T cells by p24 ELISA (Perkin Elmer Life Sciences, Walthem, MA, USA). An HIV-1 input corresponding to 30ng was used. The level of HIV-1 infection among the cells was assessed by flow cytometry.
DC-mediated HIV-1 transmission assay
Immature DCs were plated at 4 x 10 4 cells/well in a 96-well format and pulsed with the appropriate virus. After incubation, cells were washed with culture medium before addition of CD4 + -enriched T lymphocytes at a concentration of 2 x 10 5 cells/well with a final volume of 200μl. The infection was followed with HIV-1 CA-p24 ELISA or flow cytometry. Infectious doses of 50 per well were used. The inhibitory effects of Mermaid on the DC-mediated HIV-1 transfer to T cells cultures was determined by preincubation of the virus with mermaid for 30 min at 37°C. As a control, normal virus was also placed at 37°C. For experiments with mannan, both DCs and mermaid were preincubated for 30 min at 37°C with mannan (0.5 mg/ml) and subsequently used in experiments. Experiments were performed in triplicates two times in independent experiments. The results were plotted as medians of data for three samples with bars reflecting standard deviation (SD).
Apoptosis detection assay
DCs and CD4 + T cells were cultured in the presence of 20μg/ml of mermaid for 48days. The cells cultured in absence of mermaid were used as a control. The apoptosis was monitored using the number of dead cells according to forward and side scatters of FACS analysis and the staining with DNA incorporating dye, namely 7-aminoactimicin D (7-AAD; Invitrogen). 10μg/ml 7-AAD was added prior to measurement. The staining was assessed by flow cytometry (FACS Calibur, BD Biosciences).
Statistical analyses
Students T-test and ANOVA in the case of normal distributed data were used to analyse significant differences between sets of data. Data are presented as mean ± SD with P values b 0.05 (paired, twosided) considered as statistically significant. The brackets and asterix in the figures represent the statistical differences between the values: d*T corresponds to P b 0.05, d**T to 0 b 0.01 and d***T to P b 0.001.
